Skip to content
HowShorted

Corbus Pharmaceuticals Holdings, Inc. short interest in 2023

In 2023, Corbus Pharmaceuticals Holdings, Inc.'s disclosed short interest ran from 2.50% of shares outstanding on 13 Jan 2023 to 0.90% on 29 Dec 2023, a change of -1.60 percentage points. The year's high was 8.65% on 31 Mar 2023 and its low 0.90% on 29 Dec 2023, averaging 2.64% across 22 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 10.19 days on 13 Oct 2023. Full history: Corbus Pharmaceuticals Holdings, Inc..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2018 · 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026

Aggregate net short position time series for Corbus Pharmaceuticals Holdings, Inc. in 2023

2023 in figures

Start of year
2.50% (13 Jan 2023)
End of year
0.90% (29 Dec 2023)
Change
-1.60 pp
High
8.65% (31 Mar 2023)
Low
0.90% (29 Dec 2023)
Average
2.64%
Highest days to cover
10.19 (13 Oct 2023)
SEC filings marked
8

Every report in 2023

Corbus Pharmaceuticals Holdings, Inc. short interest in 2023
SettlementShort interestDays to coverFilings since previous
13 Jan 20232.50%1.86
31 Jan 20232.37%2.69
15 Mar 20233.50%1.2210-K filed, results (8-K)
31 Mar 20238.65%1.00
14 Apr 20237.13%2.15
28 Apr 20234.92%1.30
15 May 20233.35%2.8710-Q filed, results (8-K)
31 May 20232.56%2.76
15 Jun 20232.68%5.21
30 Jun 20232.69%5.46
14 Jul 20232.33%8.21
31 Jul 20232.13%5.53
15 Aug 20231.81%6.9810-Q filed, results (8-K)
31 Aug 20231.70%7.95
15 Sep 20231.48%5.95
29 Sep 20231.44%7.77
13 Oct 20231.39%10.19
31 Oct 20231.24%5.38
15 Nov 20231.28%2.5410-Q filed, results (8-K)
30 Nov 20231.03%2.54
15 Dec 20231.08%2.27
29 Dec 20230.90%1.91

See also: Corbus Pharmaceuticals Holdings, Inc.'s full history · most shorted US stocks of 2023 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.